• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥地利下奥地利州对 SARS-CoV-2 刺突蛋白特异性抗体反应的纵向监测。

Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria.

机构信息

Research Division for Neurodegenerative Diseases, Center for Biosciences, Department of Medicine, Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria.

Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR S1266, INSERM, Université de Paris, Paris, France.

出版信息

PLoS One. 2022 Jul 27;17(7):e0271382. doi: 10.1371/journal.pone.0271382. eCollection 2022.

DOI:10.1371/journal.pone.0271382
PMID:35895668
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9328535/
Abstract

The Lower Austrian Wachau region was an early COVID-19 hotspot of infection. As previously reported, in June 2020, after the first peak of infections, we determined that 8.5% and 9.0% of the participants in Weißenkirchen and surrounding communities in the Wachau region were positive for immunoglobulin G (IgG) and immunoglobulin A (IgA) antibodies against the receptor-binding domain of the spike protein of SARS-CoV-2, respectively. Here, we present novel data obtained eight months later (February 2021) from Weißenkirchen, after the second peak of infection, with 25.0% (138/552) and 23.6% (130/552) of participants that are positive for IgG and IgA, respectively. In participants with previous IgG/IgA positivity (June 2020), we observed a 24% reduction in IgG levels, whereas the IgA levels remained stable in February 2021. This subgroup was further analyzed for SARS-CoV-2 induced T cell activities. Although 76% (34/45) and 76% (34/45) of IgG positive and IgA positive participants, respectively, showed specific T cell activities (upon exposure to SARS-CoV-2 spike protein-derived peptides), those were not significantly correlated with the levels of IgG or IgA. Thus, the analyses of antibodies cannot surrogate the measurement of T cell activities. For a comprehensive view on SARS-CoV-2-triggered immune responses, the measurement of different classes of antibodies should be complemented with the determination of T cell activities.

摘要

下奥地利州瓦豪地区是 COVID-19 感染的早期热点地区。如前所述,在 2020 年 6 月,在感染的第一个高峰之后,我们发现瓦豪地区魏森基兴及其周边社区的参与者中,分别有 8.5%和 9.0%的人对 SARS-CoV-2 刺突蛋白受体结合域的免疫球蛋白 G(IgG)和免疫球蛋白 A(IgA)抗体呈阳性。在这里,我们呈现了八个月后(2021 年 2 月)从魏森基兴获得的新数据,在第二次感染高峰后,有 25.0%(138/552)和 23.6%(130/552)的参与者 IgG 和 IgA 呈阳性。在之前 IgG/IgA 阳性的参与者中(2020 年 6 月),我们观察到 IgG 水平下降了 24%,而 IgA 水平在 2021 年 2 月保持稳定。对该亚组进行了 SARS-CoV-2 诱导的 T 细胞活性分析。虽然分别有 76%(34/45)和 76%(34/45)的 IgG 阳性和 IgA 阳性参与者显示出特异性 T 细胞活性(在接触 SARS-CoV-2 刺突蛋白衍生肽后),但这些活性与 IgG 或 IgA 的水平没有显著相关性。因此,抗体分析不能替代 T 细胞活性的测量。为了全面了解 SARS-CoV-2 触发的免疫反应,应将不同类别的抗体测量与 T 细胞活性的测定相结合。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5147/9328535/ec9ce6b07b0c/pone.0271382.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5147/9328535/c001429fd8b8/pone.0271382.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5147/9328535/061a5fc2d4a0/pone.0271382.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5147/9328535/ec9ce6b07b0c/pone.0271382.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5147/9328535/c001429fd8b8/pone.0271382.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5147/9328535/061a5fc2d4a0/pone.0271382.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5147/9328535/ec9ce6b07b0c/pone.0271382.g003.jpg

相似文献

1
Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria.奥地利下奥地利州对 SARS-CoV-2 刺突蛋白特异性抗体反应的纵向监测。
PLoS One. 2022 Jul 27;17(7):e0271382. doi: 10.1371/journal.pone.0271382. eCollection 2022.
2
Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.采用微阵列和其他 12 种免疫分析法评估急性 SARS-CoV-2 感染中 S1、S2 和 NCP 特异性 IgM、IgA 和 IgG 抗体的动力学。
J Clin Microbiol. 2021 Apr 20;59(5). doi: 10.1128/JCM.02890-20.
3
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.COVID-19 患者血清和唾液中针对 SARS-CoV-2 刺突抗原的抗体反应持续存在。
Sci Immunol. 2020 Oct 8;5(52). doi: 10.1126/sciimmunol.abe5511.
4
Detailed Multiplex Analysis of SARS-CoV-2 Specific Antibodies in COVID-19 Disease.详细的 SARS-CoV-2 特异性抗体的多重分析在 COVID-19 疾病中。
Front Immunol. 2021 Jun 10;12:695230. doi: 10.3389/fimmu.2021.695230. eCollection 2021.
5
Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.四种 SARS-CoV-2 抗体检测试剂在 COVID-19 患者及细菌性和非 SARS-CoV-2 病毒呼吸道感染患者中的诊断性能比较。
Eur J Clin Microbiol Infect Dis. 2021 Sep;40(9):1983-1997. doi: 10.1007/s10096-021-04285-4. Epub 2021 Jun 9.
6
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.接种灭活疫苗后 160 天内血清抗 SARS-CoV-2 抗体的反应和持续时间。
Front Immunol. 2021 Dec 23;12:786554. doi: 10.3389/fimmu.2021.786554. eCollection 2021.
7
Immune Response of Neonates Born to Mothers Infected With SARS-CoV-2.感染 SARS-CoV-2 的母亲所生新生儿的免疫反应。
JAMA Netw Open. 2021 Nov 1;4(11):e2132563. doi: 10.1001/jamanetworkopen.2021.32563.
8
Descriptive evaluation of antibody responses to severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in plasma and gingival crevicular fluid in a nursing home cohort-Arkansas, June-August 2020.描述性评估养老院队列中血浆和龈沟液中针对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的抗体反应-阿肯色州,2020 年 6 月至 8 月。
Infect Control Hosp Epidemiol. 2022 Nov;43(11):1610-1617. doi: 10.1017/ice.2021.484. Epub 2021 Nov 22.
9
Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension.急危重症高血压患者的 SARS-CoV-2 特异性动态免疫。
Front Immunol. 2020 Dec 10;11:596684. doi: 10.3389/fimmu.2020.596684. eCollection 2020.
10
Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019.新冠肺炎患者不同严重程度的新冠病毒抗体反应。
PLoS One. 2020 Oct 9;15(10):e0240502. doi: 10.1371/journal.pone.0240502. eCollection 2020.

引用本文的文献

1
Humoral response against COVID-19 in the population of western region of Poland.波兰西部地区人群对新冠病毒的体液免疫反应。
Front Public Health. 2025 Aug 5;13:1648937. doi: 10.3389/fpubh.2025.1648937. eCollection 2025.
2
Anti-SARS-CoV-2 IgG Seroprevalence in Tyrol, Austria, among 28,768 Blood Donors between May 2022 and March 2023.2022年5月至2023年3月期间奥地利蒂罗尔州28768名献血者中的抗SARS-CoV-2 IgG血清流行率。
Vaccines (Basel). 2024 Mar 8;12(3):284. doi: 10.3390/vaccines12030284.
3
Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022.

本文引用的文献

1
Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults.中和新冠病毒受体结合域特异性抗体在成年人中持续至少六个月,与症状无关。
Commun Med (Lond). 2021 Jul 14;1:13. doi: 10.1038/s43856-021-00012-4. eCollection 2021.
2
Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.康复的 COVID-19 患者中严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)刺突蛋白特异性和中和抗体的长期持久性。
PLoS One. 2022 Apr 21;17(4):e0267102. doi: 10.1371/journal.pone.0267102. eCollection 2022.
3
奥地利蒂罗尔州抗 SARS-CoV-2 IgG 抗体的血清流行率:2021 年 10 月至 2022 年 4 月期间涉及 22607 名献血者的更新分析。
Viruses. 2022 Aug 25;14(9):1877. doi: 10.3390/v14091877.
Model based estimation of the SARS-CoV-2 immunization level in austria and consequences for herd immunity effects.
基于模型的奥地利 SARS-CoV-2 免疫水平估计及其对群体免疫效果的影响。
Sci Rep. 2022 Feb 21;12(1):2872. doi: 10.1038/s41598-022-06771-x.
4
Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection.分析 COVID-19 中的抗体反应模式:SARS-CoV-2 感染演变中的 Spike S1 反应性 IgA 特征。
Front Immunol. 2021 Nov 3;12:772239. doi: 10.3389/fimmu.2021.772239. eCollection 2021.
5
Persisting Antibody Response to SARS-CoV-2 in a Local Austrian Population.奥地利当地人群对新冠病毒的持续抗体反应。
Front Med (Lausanne). 2021 Jun 17;8:653630. doi: 10.3389/fmed.2021.653630. eCollection 2021.
6
Persistence of humoral response upon SARS-CoV-2 infection.SARS-CoV-2 感染后体液免疫应答的持久性。
Rev Med Virol. 2022 Mar;32(2):e2272. doi: 10.1002/rmv.2272. Epub 2021 Jun 30.
7
SARS-CoV-2-Specific Antibody Prevalence and Symptoms in a Local Austrian Population.奥地利当地人群中针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的抗体流行率及症状
Front Med (Lausanne). 2021 May 24;8:632942. doi: 10.3389/fmed.2021.632942. eCollection 2021.
8
Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study.2020 年丹麦对 400 万 PCR 检测个体进行的 SARS-CoV-2 再感染保护评估:一项基于人群的观察性研究。
Lancet. 2021 Mar 27;397(10280):1204-1212. doi: 10.1016/S0140-6736(21)00575-4. Epub 2021 Mar 17.
9
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals.T 细胞和抗体动力学描绘了 COVID-19 恢复期个体中介导长期免疫反应的 SARS-CoV-2 肽。
Sci Transl Med. 2021 Apr 21;13(590). doi: 10.1126/scitranslmed.abf7517. Epub 2021 Mar 15.
10
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19.SARS-CoV-2 轻症至中度 COVID-19 患者的免疫应答演变。
Nat Commun. 2021 Feb 19;12(1):1162. doi: 10.1038/s41467-021-21444-5.